Navigation Links
Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
Date:9/3/2008

y include unusual tiredness and clumsiness, muscle weakness, slurred speech, and difficulty swallowing. As the disease progresses, patients gradually lose the use of their hands, arms, legs, and neck muscles, ultimately becoming paralyzed. They can speak and swallow only with great difficulty. About half of people with ALS die within three to five years of diagnosis.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to clinical trials of SB-509 and the potential for further study and development of SB-509, research and development
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com announces addition ... Guidebook Series (4) 2013 Edition Material and Clinical ... Drug Registration: A Guidebook of Registration Application for ... to its online database. The traditional ... are always regarded by occidental as mysterious medicines. ...
(Date:5/22/2013)... VANCOUVER, British Columbia , May 22, 2013  OncoGenex ... the development of novel therapeutics to target mechanisms of treatment ... investigational compounds, custirsen and OGX-427, will be presented as "Trials ... of the American Society of Clinical Oncology (ASCO) in ... 4. Despite the availability of drugs that ...
(Date:5/21/2013)... 2013 Concord Medical Services Holdings Limited ("Concord ... a leading specialty hospital management solution provider and operator ... centers in China and the parent of Chang,an Hospital, ... first quarter ended March 31, 2013 [1] . ... revenue, which consists of net revenues generated from the ...
Breaking Medicine Technology:China Pharmaceutical Market Guidebook Series (4) 2013 Report 2China Pharmaceutical Market Guidebook Series (4) 2013 Report 3China Pharmaceutical Market Guidebook Series (4) 2013 Report 4China Pharmaceutical Market Guidebook Series (4) 2013 Report 5OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 2OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 3OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 4OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 5Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13
... 28, 2011 Pharmasset, Inc. (Nasdaq: VRUS ) ... Conference being held May 2 to 4, 2011 at the ... Merrill Lynch Healthcare Conference being held May 10 to 12, ... Price, Pharmasset,s President and Chief Executive Officer, will provide an ...
... 28, 2011 The U.S. Food and Drug ... with prednisone (a steroid) to treat patients with ... prior docetaxel (chemotherapy). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... sex hormone testosterone stimulates prostate tumors to grow. ...
Cached Medicine Technology:Pharmasset to Present at Two Upcoming Investor Conferences 2Pharmasset to Present at Two Upcoming Investor Conferences 3FDA Approves Zytiga for Late-Stage Prostate Cancer 2FDA Approves Zytiga for Late-Stage Prostate Cancer 3
(Date:5/22/2013)... 21 May 2013, Paris, France: Results from ... 2013 today question whether bivalirudin is superior ... blockade, showing similar 30-day mortality in patients ... (NSTE-ACS) undergoing percutaneous coronary intervention (PCI)., European ... alone as an alternative to unfractionated heparin ...
(Date:5/22/2013)... 2013 In the past decade, ... and courts with donated uniforms, shoes, balls and ... dedicated to partnering with manufacturers to provide youth with ... of $8.8 million in sports and fitness equipment over ... kids outfitted for physical activity. , An inaugural ...
(Date:5/22/2013)... Following the success of last year’s 1,000 ... Body Boot Camp Kincardine has announced it will be ... on June 3rd at its Kincardine fitness center ... Ontario.     , Fit Body Boot Camp’s 1,000 lb. Meltdown ... residents to lose a total of 1,000 pounds in ...
(Date:5/22/2013)... NJ (PRWEB) May 22, 2013 ... and management solutions for social enterprise collaboration platforms, ... a consulting firm based in Chicago, Ill. The ... their products and provide best-in-class solutions for SharePoint ... improve collaboration. , AvePoint’s DocAve Software Platform ...
(Date:5/22/2013)... 2013 Poor adherence to appropriate medication ... medical complications and death (some 125,000 deaths in the ... increased health-care costs. It’s been estimated that between 33% ... to poor medication adherence — a reality that costs ... Indeed, so dire is the degree of medication non-adherence ...
Breaking Medicine News(10 mins):Health News:Registry questions superiority of bivalirudin over heparin 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 2Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 3Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2
... ... the latest technologies in Refractive and Corneal Surgery. , ... (Vocus) March 30, 2010 -- The Khanna Institute opens new office ... cities in the world. The city is known for its famous zip code, phenomenal shopping ...
... for this common condition, researchers say , TUESDAY, March 30 ... known as deep vein thrombosis, it is most likely to ... leg, Canadian researchers have found. , Dr. Wee-Shian Chan ... newly published review, said in a news release that the ...
... Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs ... symptoms of arthritis and other inflammatory disorders. But ... have osteoarthritis) these medications are also known to ... body, particularly in the gastrointestinal tract. ...
... that point to spectrum disorders , TUESDAY, March 30 ... brain proteins that seem to be linked to autism ... the most comprehensive genetic analyses of association between these ... disorder] risk," said Anthony Monaco, of the Wellcome Trust ...
... dying rose among older people cared for in minority ... many supportive relatives actually increases the fear of dying ... researchers. , The finding runs counter to the common ... the fear of death. It also has important implications ...
... has been thought that the loss of physical and psychological ... in brain structures. However, in the current edition of ... 107[12]: 199-205), Rainer Scheid and D. Yves von Cramon conclude ... brain injury is more frequent than stroke and is mostly ...
Cached Medicine News:Health News:The Khanna Institute of LASIK and Refractive Surgery Opens New Office in Beverly Hills 2Health News:McMaster researcher leads development of promising drug for inflammation 2Health News:More Family Support Can Raise Fears For Some Elderly 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: